JP2013242298A5 - - Google Patents

Download PDF

Info

Publication number
JP2013242298A5
JP2013242298A5 JP2013071040A JP2013071040A JP2013242298A5 JP 2013242298 A5 JP2013242298 A5 JP 2013242298A5 JP 2013071040 A JP2013071040 A JP 2013071040A JP 2013071040 A JP2013071040 A JP 2013071040A JP 2013242298 A5 JP2013242298 A5 JP 2013242298A5
Authority
JP
Japan
Prior art keywords
chemotherapy
determining
administration
biological sample
effect
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013071040A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013242298A (ja
JP6175711B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority to JP2013071040A priority Critical patent/JP6175711B2/ja
Priority claimed from JP2013071040A external-priority patent/JP6175711B2/ja
Publication of JP2013242298A publication Critical patent/JP2013242298A/ja
Publication of JP2013242298A5 publication Critical patent/JP2013242298A5/ja
Application granted granted Critical
Publication of JP6175711B2 publication Critical patent/JP6175711B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013071040A 2012-04-26 2013-03-29 Ｓ−１による癌化学療法の投与効果の判定方法 Expired - Fee Related JP6175711B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2013071040A JP6175711B2 (ja) 2012-04-26 2013-03-29 Ｓ−１による癌化学療法の投与効果の判定方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2012100681 2012-04-26
JP2012100681 2012-04-26
JP2013071040A JP6175711B2 (ja) 2012-04-26 2013-03-29 Ｓ−１による癌化学療法の投与効果の判定方法

Publications (3)

Publication Number Publication Date
JP2013242298A JP2013242298A (ja) 2013-12-05
JP2013242298A5 true JP2013242298A5 (https=) 2016-05-19
JP6175711B2 JP6175711B2 (ja) 2017-08-09

Family

ID=49477808

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013071040A Expired - Fee Related JP6175711B2 (ja) 2012-04-26 2013-03-29 Ｓ−１による癌化学療法の投与効果の判定方法

Country Status (2)

Country Link
US (1) US9494594B2 (https=)
JP (1) JP6175711B2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6588495B2 (ja) * 2017-05-01 2019-10-09 日本電信電話株式会社 分析システム、設定方法および設定プログラム

Similar Documents

Publication Publication Date Title
Holm et al. Bile salts and their importance for drug absorption
Nielsen et al. Implications of ABCG2 expression on irinotecan treatment of colorectal cancer patients: a review
Wang et al. Plumbagin induces cell cycle arrest and autophagy and suppresses epithelial to mesenchymal transition involving PI3K/Akt/mTOR-mediated pathway in human pancreatic cancer cells
MY187050A (en) Cancer cell-specific antibody, anticancer agent, and cancer testing method
EA201490815A1 (ru) Составы этанерцепта, стабилизированные с помощью аминокислот
JP2013527832A5 (https=)
BR112014017518A8 (pt) anticorpo e ácido nucleico isolados, célula hospedeira, métodos, imunoconjugado, formulação farmacêutica e uso do anticorpo
Chen et al. Chloroquine potentiates the anticancer effect of pterostilbene on pancreatic cancer by inhibiting autophagy and downregulating the RAGE/STAT3 pathway
Corro et al. Emerging trends for radio-immunotherapy in rectal cancer
De et al. Bête noire of chemotherapy and targeted therapy: CAF-mediated resistance
JP2013527437A5 (https=)
BR112014011758A2 (pt) composição farmacêutica, proteína de fusão, polinucleotídeo, vetor, célula isolada, métodos para produzir uma proteína de fusão, para tratar ou previnir uma doença ou condição, para diagnosticar a suscetibilidade de um indivíduo a desenvolver uma doença ou condição, para determinar uma adequabilidade do indivíduo para ingressar em um experimento de classificação dedroga, e para identificar um agente, uso de uma combinação, e, combinação.
CA2872275C (en) Stabilized formulations containing anti-dll4 antibodies
Kacan et al. Antitumor activity of sorafenib on colorectal cancer
WO2014117680A3 (zh) 外周血细胞TRPC6mRNA水平用于早期预测/诊断老年性痴呆
Anand et al. Cisplatin-Loaded M1 Macrophage-Derived Vesicles Have Anti-Cancer Activity in Osteosarcoma
JP2013242298A5 (https=)
JP2022500638A5 (https=)
Rizzo et al. Systemic treatment for metastatic biliary tract cancer: state of the art and a glimpse to the future
JP2015180198A5 (https=)
JP2015517500A5 (https=)
CN109690316A (zh) 测定细胞内配体靶蛋白相互作用持久力的方法
Hassel et al. RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma
Yu et al. Pharmacokinetics and Pharmacodynamics of MEDI4893, an Investigational Anti-Staphylococcus Aureus Alpha Toxin Human Monoclonal Antibody, in Healthy Adults: A Phase 1, Randomised Placebo-Controlled Study
JP2016188260A5 (https=)